Koln, Germany
Cannamedical Pharma, recognized as Europe's Leading Cannabis Brand, stands out in the health care and pharmaceutical sectors with its unique market positioning. Established in 2016, the company has successfully carved a niche as an independent German cannabis wholesaler, distinguished by its pharmaceutical wholesale license and narcotics handling permit. This regulatory compliance underscores their reliability and trustworthiness in the German market.
Leveraging partnerships with select international producers, Cannamedical Pharma offers a diverse range of medical cannabis products, reinforcing their pledge to uphold high quality standards. As a pioneer in the European cannabis landscape, the company excels in GMP processing and authority auditing, equipping them to maintain an ethical and professional service.
The company's commitment was bolstered by a substantial €15.00M Series A investment in early 2019 from Orkila Capital. This funding highlights investor confidence and positions Cannamedical Pharma for sustained growth and leadership in the evolving European cannabis market.
